Inomin Mines Inc.: Inomin Closes $615,499 Private Placement Financing

Inomin Mines Inc. (TSXV: MINE) ("Inomin" or the "Company") is pleased to announce that it has closed its previously announced non-brokered ...

Universal Music Group Rejects Pershing Square Proposal

Universal Music Group N.V. (UMG.AS, UNVGY, UMGNF), the Dutch-American music-based entertainment company, announced that its Board of Directors has unanimously determined that ...

ThreeD Capital Inc. Releases Results For the Three and Nine Months Ended March 31, 2026

ThreeD Capital Inc. ("ThreeD" or the "Company") (CSE:IDK / OTCQB:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies ...

Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules

Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul ...
Finanznachrichten

Pfizer: Phase 3 Trial Shows TALZENNA + XTANDI Cut Progression Risk 52% In HRR-mutated MCSPC

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced detailed results from the pivotal Phase 3 TALAPRO-3 study evaluating TALZENNA (talazoparib), an oral PARP inhibitor, in combination with XTANDI ...

Lupin Limited: Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets

Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the United States Food and Drug ...

K92 Mining Inc.: K92 Mining Announces Voting Results of Annual General Meeting of Shareholders

K92 Mining Inc. ("K92" or the "Company") (TSX: KNT; OTCQX: KNTNF) is pleased to announce the voting results of its 2026 annual general meeting ...

Johnson & Johnson: RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small ...

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent ...

Nordic Fibreboard AS unaudited financial report for the Q1 of 2026

MANAGEMENT REPORT Nordic Fibreboard AS consolidated net revenue in Q1 2026 was €1.86 million, representing a 7.3% increase compared to the same period of the previous year (Q1 2025: €1.74 million), re ...

Kane Biotech Inc.: Kane Biotech Announces Grant of Stock Options

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 29, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the ...
Finanznachrichten

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LRMolecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...
Finanznachrichten

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer ...